title: [Complex effects of cavinton on climacteric symptoms].
abstract: The use of nonhormonal drugs in order to ameliorate climacteric symptoms makes it possible to treat also those women in whom there are some contraindications or lack of compliance for taking hormonal replacement therapy. The drugs with complex effects on the whole body functions are more widely used recently. The aim of the present study is to assess the therapeutic effect of Cavinton (vinpocetin) on the degree of climacteric symptoms and to verify its complex beneficial influence. The study comprises of three groups of women in early menopause--control group (n = 30), treatment groups with normolipidaemia (n = 32) and with hyperlipidaemia (n = 29). All women presented with moderately expressed climacteric symptoms as assessed by Kupperman menopausal index and Hamilton-Anxiety-Skala (HAMA). The women in the 2nd and 3rd groups have been taking Cavinton in an oral dose of 5 mg three times daily for 3 months. The following parameters of lipid metabolism were determined in the beginning and at the end of the study: total, HDL- and LDL-cholesterol, triglycerides, and two indexes of lipid atherogenic risk--total/HDL-cholesterol ratio and atherogenic index (AI) = total--HDL/LDL-cholesterol. The menopausal complaints were assessed by Kupperman index and HAMA. Blood vessels reactivity was determined by pulsation index (PI). Statistically significant decrease in total cholesterol and LDL-cholesterol levels as well as amelioration of atherogenic indexes was observed in the 3rd group. Kupperman index and HAMA decreased significantly on the 45th day and the 3rd month in the women under treatment. No significant changes in PI were observed but a tendency towards a decrease was seen in the 3rd group. Our data suggest that Cavinton possesses complex beneficial effects in climacteric women significantly ameliorating climacteric symptoms as well as some parameters of lipid metabolism in women with hyperlipidaemia.
authors.forename: G
authors.initials: G
authors.lastname: Kolarov
authors.forename: M
authors.initials: M
authors.lastname: Orbetsova
authors.forename: B
authors.initials: B
authors.lastname: Nalbanski
authors.forename: Z
authors.initials: Z
authors.lastname: Kamenov
authors.forename: S
authors.initials: S
authors.lastname: Georgiev
authors.forename: E
authors.initials: E
authors.lastname: Filipov
authors.forename: Iu
authors.initials: Iu
authors.lastname: Petrova
authors.forename: B
authors.initials: B
authors.lastname: Marinov
authors.forename: G
authors.initials: G
authors.lastname: Georgiev
mesh_terms: D000284:Administration, Oral; D001794:Blood Pressure / Q000187:drug effects; D002979:Climacteric / Q000187:drug effects* / Q000523:psychology*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D008055:Lipids; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine